Allergan, Inc.

Allergan, Inc.

Sector: Pharmaceutical Preparations Region: CA, United States

: | New York Stock Exchange: AGN

Similar to: Ipsen SA, United-Guardian, Inc., Hutchison China MediTech Ltd.

Allergan, Inc. operates as a global healthcare company. It engages in the developing and commercializing innovative specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries. The company operates through two business segments: Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a broad range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, retinal diseases and ocular surface disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis and eyelashes; and over-the-counter skin care products and urologic products. The Medical Devices segment produces a broad range of medical devices, including breast implants for augmentation, revision and reconstructive surgery; obesity intervention products, including the Lap-Band System and the Orbera Intragastric Balloon System and facial aesthetics products. Its products are sold to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers and medical practitioners. The company was founded by Gavin S. Herbert in 1950 and is headquartered in Irvine, CA.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

S&P Capital IQ Focus Stock: Allergan Inc.

S&P Capital IQ Equity Analyst Herman Saftlas has a 5-STARS "Strong Buy" recommendation for Allergan Inc. For more information, please visit: Follow us on Twitter @spmarketscope for more Trends & Ideas, ranking changes, and investment strategies.

Allergan, Inc. video

S&P Capital IQ Focus Stock: Allergan Inc.

Allergan, Inc. video

Allergan's Pyott Sees Botox Sales Growing 10% This Year

Allergan, Inc. video

Cramer Interviews Allergan CEO


David E.I. Pyott, Chairman of the Board, President & CEO
Mr. Pyott joined Allergan in January 1998 as President and Chief Executive Officer (CEO) and now serves as Chairman of the Board (since 2001), President and CEO. Previously, he was head of the Nutrition Division and a member of the Executive Committee of Novartis AG from 1995 through 1997. Mr. Pyott has about 30 years of international experience in nutrition and health care and has worked in Austria, Germany, the Netherlands, Spain, Switzerland, Malaysia, Singapore, and the United Kingdom. Mr. Pyott holds a diploma in European and International Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School. He also has been honored in the Queen’s Birthday Honors List in 2006 and holds the title of Commander of the British Empire.
Jeffrey L. Edwards, Chief Financial Officer
Mr. Edwards has been Executive Vice President, Finance and Business Development, Chief Financial Officer, since September 2005. Mr. Edwards joined Allergan in 1993. From March 2003 to September 2005, Mr. Edwards served as Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards completed the Advanced Management Program at the Harvard Business School and received a Bachelor of Arts degree in Sociology from Muhlenberg College.
Scott M. Whitcup, M.D., Chief Scientific Officer
Dr. Whitcup has been Executive Vice President, Research and Development since July 2004 and in April 2009 became Chief Scientific Officer. Dr. Whitcup joined Allergan in 2000. Prior to joining Allergan, Dr. Whitcup served as the Clinical Director of the National Eye Institute at the National Institutes of Health. As Clinical Director, Dr. Whitcup’s leadership was vital in building the clinical research program and developing new therapies for ophthalmic diseases. Dr. Whitcup graduated from Cornell University and Cornell University Medical College. He completed residency training in internal medicine at the University of California, Los Angeles and in ophthalmology at Harvard University, as well as fellowship training in uveitis and ocular immunology at the National Institutes of Health. Dr. Whitcup is a faculty member at the Jules Stein Eye Institute/David Geffen School of Medicine at the University of California, Los Angeles.

News & Analysis

You may also be interested in: